PREVENT Cancer Preclinical Drug Development Program (PREVENT) 2019
IDIQ
Overview
Ceiling
$49,995,000
Primary Sponsoring Agency
Who Can Use
One Agency
Primary Set Aside
None
Extent Competed
Full And Open Competition
Related Opportunity
PREVENT Cancer Preclinical Drug Development Program (PREVENT) 2019 awarded by National Cancer Institute (NCI) in January 2019 accepts orders through January 2024.
The IDIQ has a reported ceiling of $49,995,000, and as of today, $42,868,669 has been obligated through the vehicle
with a total reported backlog of $865,985.
The IDIQ was awarded
full & open and has a primary NAICS code of 541714.
Status
Period of Performance
1/23/19
Start Date
1/23/24
Ordering Period End Date
Task Order Obligations and Backlog
$42.9M
Total Obligated
$42.9M
Current Award
$43.7M
Potential Award
$0.0
Funded Backlog
$866.0K
Total Backlog
Vehicle Award Share
Contractors with greatest percentage of obligations for PREVENT Cancer Preclinical Drug Development Program (PREVENT) 2019
Vehicle Award Share
Federal Award Analysis
PREVENT Cancer Preclinical Drug Development Program (PREVENT) 2019 contract spending
$-
Contracts
$-
Subcontracts
$-
Grants
$-
Subgrants
$-
Total
No Results
Calculating
Calculating
No Results
Calculating
Calculating
No Results
Calculating
Calculating
| Year | Contracts | Subcontracts | Grants | Subgrants |
|---|
No Results
Calculating
Calculating
No Results
Calculating
Calculating
Awardees
PREVENT Cancer Preclinical Drug Development Program (PREVENT) 2019 awardees
Contract Awards
PREVENT Cancer Preclinical Drug Development Program (PREVENT) 2019 task orders
Subcontract Awards